Zepbound at 5, 10 and 15 mg: what the label's own trials report
In the trial printed in Zepbound’s label, adults lost 15.0% of their body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg after 72 weeks, against 3.1% on placebo. The label approves all three as maintenance doses and names none of them as best: it says to choose on response and tolerability, and the side effects climb with the dose.
Ellis Brandt built this site’s grading methodology and maintains it. Results read from Table 2 of the Zepbound label's section 14.1. Last re-read September 2026.
Not medical advice. Semaglutide and tirzepatide are prescription-only medicines, and whether one is right for you is a question for a licensed clinician who knows your history. Everything below is quoted from the FDA-approved prescribing information, each label identified by its version and effective date. See the medical disclaimer.
What each dose did at 72 weeks
Study 1 is the trial most of these numbers come from: 2,539 adults with obesity, or with overweight and at least one weight-related condition, randomized to 5 mg, 10 mg, 15 mg or placebo for 72 weeks, everyone on a reduced-calorie diet and 150 minutes a week of activity. People with type 2 diabetes were excluded. Mean weight at the start was 104.8 kg.
Drag the table sideways to read the remaining columns.
| Arm | Mean weight change | Lost 5% or more | Lost 10% or more | Lost 15% or more | Lost 20% or more |
|---|---|---|---|---|---|
| Placebo (N=643) | −3.1% | 34.5% | 18.8% | 8.8% | 3.1% |
| Zepbound 5 mg (N=630) | −15.0% | 85.1% | 68.5% | 48.0% | 30.0% |
| Zepbound 10 mg (N=636) | −19.5% | 88.9% | 78.1% | 66.6% | 50.1% |
| Zepbound 15 mg (N=630) | −20.9% | 90.9% | 83.5% | 70.6% | 56.7% |
The gap between doses is not even. Going from 5 mg to 10 mg moved the average by 4.5 percentage points; going from 10 mg to 15 mg moved it by 1.4. Where the doses separate most is at the deep end of the range: half the patients on 10 mg and 56.7% on 15 mg lost at least a fifth of their body weight, against 30.0% on 5 mg.
Percent of body weight lost, as a least-squares mean for each arm of one 72-week trial. The track runs to 25%.
Zepbound prescribing information, section 14.1, Table 2, Study 1 (2,539 adults, 72 weeks). Four arms of one trial, which is the comparison it was designed to make. Label version 40, effective 2026-08-28, read September 2026.
The second trial, in people with type 2 diabetes
Study 2 ran the same 72 weeks in 938 adults who had type 2 diabetes and a BMI of 27 or above, and it tested only the two higher doses. The results are smaller: 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo. Of that group, 60.5% on 10 mg and 64.8% on 15 mg lost at least a tenth of their weight, against 9.5% on placebo.
Those figures belong to that trial and that population. The label prints them separately for a reason, and a reader with type 2 diabetes reading the Study 1 column is reading a number measured in people who did not have it.
What the higher doses cost
The same section reports what came with the bigger numbers. Severe gastrointestinal reactions rose across the three arms of the two pooled weight trials: 1.7% on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, against 1% on placebo. Stomach complaints in general did not, holding at 56% on all three doses against 30% on placebo, and more patients stopped treatment because of them as the dose rose: 1.9%, 3.3% and 4.3%.
Fatigue and hair loss also track the dose in this label’s tables, and both are read out in full on fatigue on the four labels and hair loss on the four labels. The stomach rates for all four products sit together on side effect rates, label by label.
What the label says about choosing a dose
The label does not name a best dose. Section 2.2 lists the maintenance dosage for weight reduction as “5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly”, and for obstructive sleep apnea as 10 mg or 15 mg. The maximum for every indication is 15 mg once weekly.
On how to land on one of the three, section 2.1 gives one sentence: “Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.” Nobody starts at a maintenance dose either. Treatment begins at 2.5 mg once weekly for four weeks, a dosage the label says is “for treatment initiation and is not approved as a maintenance dosage”, and the climb after that runs in 2.5 mg steps no closer together than four weeks. The full ladder, beside the other three products’, is on the dose escalation schedules.
Two more things the trials do not tell you. They ran for 72 weeks with at least 52 weeks at the maintenance dose, so nothing in them describes a first month or a first quarter — what the label does and does not measure early on is on Zepbound at 3 months. And every number here is an average across an arm: the label’s own distribution shows patients across the whole range, which is why it reports how many reached 5%, 10%, 15% and 20% rather than one figure.
Sources
Drag the table sideways to read the remaining columns.
| Label | Applicant on the label | SPL version | Label effective date | Where it was read |
|---|---|---|---|---|
| Zepbound (tirzepatide) | Eli Lilly and Company | 40 | 2026-08-28 | DailyMed, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b |
Every percentage is from Table 2 or section 6.1 of the Zepbound label; the dosing sentences are sections 2.1 and 2.2. Every figure and quotation comes from the label’s own tables and text. Each label is the FDA-approved version that was current when it was read in September 2026, identified in the table by its version number and effective date.
See the providers
A dose is a prescribing decision, not a purchase. What sellers charge, and whether the price moves when the dose does, is on the boards.
- Tirzepatide providersprovider board
Readers who have settled on tirzepatide and are choosing who to buy it from.
- Semaglutide providersprovider board
Readers who have settled on semaglutide and are choosing who to buy it from.
More, read from the same labels
- Semaglutide vs tirzepatidereading the label
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- How they workreading the label
The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.
- Is Ozempic insulin?reading the label
What the Ozempic label calls semaglutide, how that differs from insulin, and where insulin appears on these labels as a separate medicine.
- Zepbound vs Ozempicreading the label
Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.
- Dose escalation schedulesreading the label
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesreading the label
What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.
- Hair lossreading the label
Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.
- Fatigue and tirednessreading the label
Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.
- Missed dose rulesreading the label
The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.
- Drug interactionsreading the label
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlinereading the label
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Zepbound at 3 monthsreading the label
What the Zepbound label reports and at which weeks it reports it, and where the label's own dose schedule puts a reader at three months.
- Injecting tirzepatidereading the label
The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.
- Refrigeration and storagereading the label
How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.
- Who should not take onereading the label
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.
Week 72, Study 1
| Placebo | −3.1% |
|---|---|
| Zepbound 5 mg | −15.0% |
| Zepbound 10 mg | −19.5% |
| Zepbound 15 mg | −20.9% |
Mean weight change in one 72-week trial of 2,539 adults without type 2 diabetes. All three doses are approved maintenance dosages.